Cyclacel Pharmaceuticals (NASDAQ:CYCC) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research note issued to investors on Sunday. The firm issued a sell rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Stock Down 7.4 %

Shares of Cyclacel Pharmaceuticals stock opened at $0.30 on Friday. The company has a market cap of $1.89 million, a P/E ratio of -0.03 and a beta of 0.28. The firm’s 50 day moving average price is $0.33 and its 200-day moving average price is $0.53. Cyclacel Pharmaceuticals has a 52-week low of $0.29 and a 52-week high of $4.00.

Insider Transactions at Cyclacel Pharmaceuticals

In related news, CEO David E. Lazar sold 194,628,820 shares of the business’s stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total transaction of $5,838,864.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 23.97% of the company’s stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.